Pharmaceutical sector sees growth in GLP-1 drugs and production technology

The pharmaceutical industry is seeing significant activity within the GLP-1 market. Major drugmakers including Roche, Regeneron Pharmaceuticals, and Amgen are developing candidates to capitalize on this growth. Smaller biotechnology firms such as Viking Therapeutics and Kailera Therapeutics are also positioned in the sector, though they face higher risks due to potential clinical setbacks. Viking Therapeutics is currently conducting clinical trials for VK2735, a dual GLP-1 and GIP agonist, with results from maintenance studies and phase 3 trials expected in the coming year.

In related industry developments, Optima Pharma has appointed Christian Reichardt as Chief Technology Officer, effective April 1, 2026. Reichardt will oversee strategic technology development to support the growing demand for sterile production facilities. This demand is being driven by sectors such as biologics and GLP-1 products, alongside tightening regulatory standards like EU GMP Annex 1.